Sartorius Stedim Biotech: directors' dealings · France · AMF

About Sartorius Stedim Biotech

SARTORIUS STEDIM BIOTECH is a leading provider of technologies and consumables for the biopharmaceutical industry. Listed in Paris under ISIN FR0013154002, the company supplies critical solutions that help customers develop, test, and manufacture biologic drugs safely, efficiently, and at scale. Its business is closely tied to the structural growth of life sciences, including monoclonal antibodies, vaccines, cell and gene therapies, and more complex next-generation biologics. Sartorius Stedim Biotech positions itself as a long-term partner to pharmaceutical companies, biotechnology firms, and research organizations rather than as a simple equipment vendor. The company’s roots are linked to the broader Sartorius group, whose history dates back to 1870. Its current structure emerged from the combination of specialized Sartorius assets with Stedim, a historic bioprocessing technology company, creating a European champion that has become a global reference in bioprocess solutions. The operational headquarters is in Aubagne, France. Today, the group operates internationally with subsidiaries in more than 30 countries and over 50 locations worldwide. At the end of 2024, it employed about 9,900 people globally. Its business model is built around a broad portfolio of equipment, consumables, and services for biopharmaceutical labs and production facilities. Core product lines include filtration, separation, cell culture, fluid management and transfer, single-use mixing, and process monitoring and analytics. A major competitive strength lies in single-use technologies, which improve industrial flexibility, reduce contamination risk, and shorten production timelines. The company also develops solutions for continuous manufacturing and products tailored to advanced therapies, reinforcing its exposure to high-value, innovation-driven segments of the market. Commercially, Sartorius Stedim Biotech has a global footprint serving an international customer base. Roughly 90% of sales are linked to life science customers, highlighting the group’s strong specialization. In 2024, revenue reached approximately EUR 2.8 billion, confirming its status as a highly focused international leader with robust profitability. Even though 2024 remained challenging for the life science industry, with continued destocking and subdued customer investment, the business stabilized through the year and showed a more positive trend in the second half. The company has also continued to pursue profitable growth and portfolio expansion through acquisitions of complementary technologies, supporting its long-term strategic positioning.